These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1130 related articles for article (PubMed ID: 31307542)

  • 21. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.
    Ryan P; Mulligan AM; Aronson M; Ferguson SE; Bapat B; Semotiuk K; Holter S; Kwon J; Kalloger SE; Gilks CB; Gallinger S; Pollett A; Clarke BA
    Cancer; 2012 Feb; 118(3):681-8. PubMed ID: 21721000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome.
    Liu YL; Cadoo KA; Maio A; Patel Z; Kemel Y; Salo-Mullen E; Catchings A; Ranganathan M; Kane S; Soslow R; Ceyhan-Birsoy O; Mandelker D; Carlo MI; Walsh MF; Shia J; Markowitz AJ; Offit K; Stadler ZK; Latham A
    Genet Med; 2022 Jun; 24(6):1187-1195. PubMed ID: 35346574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lynch syndrome identification in a Brazilian cohort of endometrial cancer screened by a universal approach.
    Rosa RCA; Santis JO; Teixeira LA; Molfetta GA; Dos Santos JTT; Ribeiro VDS; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Ferraz VEF
    Gynecol Oncol; 2020 Oct; 159(1):229-238. PubMed ID: 32694065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Hampel H; Pearlman R; de la Chapelle A; Pritchard CC; Zhao W; Jones D; Yilmaz A; Chen W; Frankel WL; Suarez AA; Cosgrove C; Backes F; Copeland L; Fowler J; O'Malley D; Salani R; McElroy JP; Stanich PP; Goodfellow P; Cohn DE
    Gynecol Oncol; 2021 Jan; 160(1):161-168. PubMed ID: 33393477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart TL; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Cancer; 2021 Sep; 127(17):3082-3091. PubMed ID: 33983630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for Lynch syndrome identification in selected and unselected gynecological cancers.
    Carnevali I; Sahnane N; Chiaravalli AM; Di Lauro E; Facco C; Facchi S; Casarin J; Ghezzi F; Sessa F; Tibiletti MG
    Eur J Cancer Prev; 2022 Jul; 31(4):369-376. PubMed ID: 34519692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial screening by immunohistochemistry is effective in universal screening for Lynch syndrome in endometrial cancer patients: a prospective observational study.
    Tsuruta T; Todo Y; Yamada R; Kuwahara K; Kurosu H; Minowa K; Minoura Y; Minobe S; Suzuki H; Kato H
    Jpn J Clin Oncol; 2022 Jul; 52(7):752-758. PubMed ID: 35438162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
    Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
    Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Universal tumor screening in a population with MSH6- and PMS2-associated Lynch syndrome.
    Einarsson H; Runarsdottir JR; Tryggvason T; Snaebjornsson P; Smaradottir A; Stefansdottir V; Thoroddsen A; Arngrimsson R; Jonasson JG; Haraldsdottir S
    Genet Med; 2022 May; 24(5):999-1007. PubMed ID: 35172941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.